PDCD1 and neoplasm: Thus, in patients with breast cancer receiving neoadjuvant immunotherapy, several biomarkers are being evaluated for their association with response to PD-1 or PD-L1 inhibitors, including PD-L1 expression and tumour-infiltrating lymphocytes (TILs) [20, 46].